Brief: Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism
02/09/2025 12:46
Rezolute Inc RZLT.O: REZOLUTE ANNOUNCES ALIGNMENT WITH FDA ON STREAMLINED DESIGN FOR ONGOING PHASE 3 TRIAL OF ERSODETUG IN TUMOR HYPERINSULINISM REZOLUTE INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026 REZOLUTE INC - FDA CONFIRMS SUNRIZE TRIAL RESULTS EXPECTED IN DEC 2025 AS CLINCIAL EVIDENCE Source text: ID:nGNX7gNjPr Further company coverage: RZLT.O